These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
427 related articles for article (PubMed ID: 8603675)
1. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675 [TBL] [Abstract][Full Text] [Related]
2. Ultrastructural features and P-glycoprotein immunolocalization in Saos-2/DX580 multidrug-resistant human osteosarcoma cells. Maraldi NM; Zini N; Sabatelli P; Valmori A; Scotlandi K; Serra M; Baldini N J Submicrosc Cytol Pathol; 1996 Jan; 28(1):93-100. PubMed ID: 8929631 [TBL] [Abstract][Full Text] [Related]
3. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. Abbaszadegan MR; Cress AE; Futscher BW; Bellamy WT; Dalton WS Cancer Res; 1996 Dec; 56(23):5435-42. PubMed ID: 8968098 [TBL] [Abstract][Full Text] [Related]
4. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines. Yang C; Hornicek FJ; Wood KB; Schwab JH; Mankin H; Duan Z Cancer Chemother Pharmacol; 2009 Aug; 64(3):607-14. PubMed ID: 19125251 [TBL] [Abstract][Full Text] [Related]
5. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. Munteanu E; Verdier M; Grandjean-Forestier F; Stenger C; Jayat-Vignoles C; Huet S; Robert J; Ratinaud MH Biochem Pharmacol; 2006 Apr; 71(8):1162-74. PubMed ID: 16499877 [TBL] [Abstract][Full Text] [Related]
6. Decreased P-glycoprotein expression in multidrug-sensitive and -resistant human myeloma cells induced by the cytokine leukoregulin. Evans CH; Baker PD Cancer Res; 1992 Nov; 52(21):5893-9. PubMed ID: 1356622 [TBL] [Abstract][Full Text] [Related]
7. The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines. Featherstone JM; Speers AG; Lwaleed BA; Hayes MC; Cooper AJ; Birch BR BJU Int; 2005 May; 95(7):1091-8. PubMed ID: 15839939 [TBL] [Abstract][Full Text] [Related]
8. The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance. Abulrob AN; Mason M; Bryce R; Gumbleton M J Drug Target; 2000; 8(4):247-56. PubMed ID: 11144235 [TBL] [Abstract][Full Text] [Related]
9. Modulation of vindesine and doxorubicin resistance in multidrug-resistant pleural mesothelioma cells by tumor necrosis factor-alpha. Licht T; Lübbert M; Martens C; Bross KJ; Fiebig HH; Mertelsmann R; Herrmann F Cytokines Mol Ther; 1995 Jun; 1(2):123-32. PubMed ID: 9384669 [TBL] [Abstract][Full Text] [Related]
10. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Nakagawa M; Schneider E; Dixon KH; Horton J; Kelley K; Morrow C; Cowan KH Cancer Res; 1992 Nov; 52(22):6175-81. PubMed ID: 1358431 [TBL] [Abstract][Full Text] [Related]
11. Voacamine, an alkaloid extracted from Peschiera fuchsiaefolia, inhibits P-glycoprotein action in multidrug-resistant tumor cells. Meschini S; Marra M; Condello M; Calcabrini A; Federici E; Dupuis ML; Cianfriglia M; Arancia G Int J Oncol; 2005 Dec; 27(6):1597-603. PubMed ID: 16273216 [TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein subcellular localization and cell morphotype in MDR1 gene-transfected human osteosarcoma cells. Maraldi NM; Zini N; Santi S; Scotlandi K; Serra M; Baldini N Biol Cell; 1999 Jan; 91(1):17-28. PubMed ID: 10321019 [TBL] [Abstract][Full Text] [Related]
13. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Keizer HG; Schuurhuis GJ; Broxterman HJ; Lankelma J; Schoonen WG; van Rijn J; Pinedo HM; Joenje H Cancer Res; 1989 Jun; 49(11):2988-93. PubMed ID: 2566376 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Slovak ML; Hoeltge GA; Dalton WS; Trent JM Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069 [TBL] [Abstract][Full Text] [Related]
15. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093 [TBL] [Abstract][Full Text] [Related]
16. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line. Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825 [TBL] [Abstract][Full Text] [Related]
17. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143 [TBL] [Abstract][Full Text] [Related]
18. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852 [TBL] [Abstract][Full Text] [Related]
19. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity. Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233 [TBL] [Abstract][Full Text] [Related]
20. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]